Pfizer is continuing its commitment to the UK Life Sciences sector by today announcing a £5 million investment in its Discovery Park site in Sandwich, Kent. The news coincides with the Medicines Manufacturing Industry Partnership (MMIP) annual conference, this year hosted by Pfizer at Discovery Park, which will celebrate the UK as a world-leader in medicines manufacturing.
Today’s investment will enhance Pfizer’s patient-centric design and manufacturing capability for paediatric medicines in clinical trials. The sum will cover the cost of a highly-specialised novel manufacturing technology enabling scientists to explore innovative ways to make medicines more palatable with flexible dosing for children – amplifying the company’s patient-first approach.
This investment – which underscores the special connection Pfizer holds with the local Kent area – is the latest in a series of investments Pfizer has made in advanced manufacturing technology at its site in Sandwich. Totalling £36 million since 2018 and leading to renewed growth and 80 new scientific jobs, these investments form part of Pfizer’s ongoing strategy to invest in research and development.
Mayer Schreiber, CEO of Discovery Park, Discovery Park said: “Discovery Park is a thriving part of the South East’s life science community, working with its tenants and partners to build a world-leading science park with a focus on manufacturing and digital transformation. We are delighted that Pfizer is continuing to invest in world-class science and technology at the site helping to drive innovation. In addition, Discovery Park welcomes the new source of venture capital funding via Kent County Council for life sciences businesses on the Park.”
Julian Thompson, Vice President, Global Regulatory Operations and Sandwich Site Head, Pfizer UK, said: “Today’s announcement builds on a series of investments we have made to this site over the last few years and further reinforces our commitment to progressing science here in the UK.”